MX2023002468A - Sales, cristales y cocristales novedosos. - Google Patents
Sales, cristales y cocristales novedosos.Info
- Publication number
- MX2023002468A MX2023002468A MX2023002468A MX2023002468A MX2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- crystals
- novel salts
- receptor
- sert
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075019P | 2020-09-04 | 2020-09-04 | |
| PCT/US2021/071366 WO2022051770A2 (en) | 2020-09-04 | 2021-09-03 | Novel salts, crystals, and co-crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002468A true MX2023002468A (es) | 2023-03-23 |
Family
ID=80492079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002468A MX2023002468A (es) | 2020-09-04 | 2021-09-03 | Sales, cristales y cocristales novedosos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230312573A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4208434A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023540506A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230104121A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116113622A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021338439A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186537A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300886A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002468A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022051770A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600325A4 (en) | 2017-03-24 | 2021-01-06 | Intra-Cellular Therapies, Inc. | UNIQUE COMPOSITIONS AND PROCESSES |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| SMT202600133T1 (it) | 2018-03-23 | 2026-05-12 | Intra Cellular Therapies Inc | Composti organici |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| US20250352469A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices, and methods |
| CN118566395B (zh) * | 2024-08-02 | 2024-10-25 | 则正(济南)生物科技有限公司 | 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281050B2 (en) * | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
| WO2017172811A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| EP3600325A4 (en) * | 2017-03-24 | 2021-01-06 | Intra-Cellular Therapies, Inc. | UNIQUE COMPOSITIONS AND PROCESSES |
| WO2018189646A1 (en) * | 2017-04-10 | 2018-10-18 | Dr. Reddy's Laboratories Limited | AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE |
| WO2019067591A1 (en) * | 2017-09-26 | 2019-04-04 | Intra-Cellular Therapies, Inc. | NEW SALTS AND CRYSTALS |
| BR112020024885A2 (pt) * | 2018-06-06 | 2021-03-09 | Intra-Cellular Therapies, Inc. | Novos sais e cristais |
| RS67906B1 (sr) * | 2018-06-11 | 2026-04-30 | Intra Cellular Therapies Inc | Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina |
| US12144808B2 (en) * | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2020112941A2 (en) * | 2018-11-27 | 2020-06-04 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
| EP4134101A1 (en) * | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| JP2022549335A (ja) * | 2019-09-25 | 2022-11-24 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
-
2021
- 2021-09-03 IL IL300886A patent/IL300886A/en unknown
- 2021-09-03 AU AU2021338439A patent/AU2021338439A1/en active Pending
- 2021-09-03 US US18/043,959 patent/US20230312573A1/en active Pending
- 2021-09-03 KR KR1020237010822A patent/KR20230104121A/ko active Pending
- 2021-09-03 JP JP2023514771A patent/JP2023540506A/ja active Pending
- 2021-09-03 EP EP21865304.6A patent/EP4208434A4/en active Pending
- 2021-09-03 CN CN202180054461.5A patent/CN116113622A/zh active Pending
- 2021-09-03 CA CA3186537A patent/CA3186537A1/en active Pending
- 2021-09-03 WO PCT/US2021/071366 patent/WO2022051770A2/en not_active Ceased
- 2021-09-03 MX MX2023002468A patent/MX2023002468A/es unknown
-
2026
- 2026-04-01 JP JP2026060121A patent/JP2026117004A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022051770A3 (en) | 2022-04-14 |
| EP4208434A4 (en) | 2024-10-16 |
| JP2023540506A (ja) | 2023-09-25 |
| US20230312573A1 (en) | 2023-10-05 |
| CN116113622A (zh) | 2023-05-12 |
| AU2021338439A1 (en) | 2023-02-23 |
| EP4208434A2 (en) | 2023-07-12 |
| CA3186537A1 (en) | 2022-03-10 |
| IL300886A (en) | 2023-04-01 |
| WO2022051770A2 (en) | 2022-03-10 |
| KR20230104121A (ko) | 2023-07-07 |
| JP2026117004A (ja) | 2026-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022051770A3 (en) | Novel salts, crystals, and co-crystals | |
| MX2020000967A (es) | Compuestos organicos. | |
| Kiss et al. | Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile | |
| JP2019513143A5 (cg-RX-API-DMAC7.html) | ||
| MX2022007105A (es) | Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico. | |
| BR112019019928A2 (pt) | derivados de indolina substituídos como inibidores da replicação viral da dengue | |
| JP2019513140A5 (cg-RX-API-DMAC7.html) | ||
| JP2014525470A5 (cg-RX-API-DMAC7.html) | ||
| RU2006135652A (ru) | Производные индол-1-илуксусной кислоты | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| UY28578A1 (es) | Derivados de amida | |
| NO20074781L (no) | 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer | |
| BR112019020175A2 (pt) | Derivados de indolina substituídos como inibidores da replicação viral da dengue | |
| BR112016022785B1 (pt) | Composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3-dioxigenase (ido), composição farmacêutica, e, uso de composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3dioxigenase (ido) ou de um sal farmaceuticamente aceitável do mesmo para fabricação de um medicamento | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| UA125296C2 (uk) | Заміщені похідні індоліну як інгібітори реплікації вірусів денге | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| MX2021000841A (es) | Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4. | |
| WO2023178111A3 (en) | Organic compounds | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| CR20200355A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| JP2018530608A5 (cg-RX-API-DMAC7.html) | ||
| MX2025007656A (es) | Gamma-carbolinas heterociclicas fusionadas que actuan en el receptor de serotonina 5-ht2a | |
| JP6877359B2 (ja) | イミダゾール誘導体 |